These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
178 related items for PubMed ID: 10971781
1. Leflunomide and rheumatoid arthritis: a systematic review of effectiveness, safety and cost implications. Hewitson PJ, Debroe S, McBride A, Milne R. J Clin Pharm Ther; 2000 Aug; 25(4):295-302. PubMed ID: 10971781 [Abstract] [Full Text] [Related]
2. Efficacy and safety of leflunomide in active rheumatoid arthritis. Smolen JS, Emery P. Rheumatology (Oxford); 2000 Jun; 39 Suppl 1():48-56. PubMed ID: 11001380 [Abstract] [Full Text] [Related]
3. Leflunomide: a review of its use in active rheumatoid arthritis. Prakash A, Jarvis B. Drugs; 1999 Dec; 58(6):1137-64. PubMed ID: 10651393 [Abstract] [Full Text] [Related]
4. Leflunomide in the treatment of rheumatoid arthritis. Li EK, Tam LS, Tomlinson B. Clin Ther; 2004 Apr; 26(4):447-59. PubMed ID: 15189743 [Abstract] [Full Text] [Related]
5. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, Loew-Friedrich I, Oed C, Rosenburg R. Lancet; 1999 Jan 23; 353(9149):259-66. PubMed ID: 9929017 [Abstract] [Full Text] [Related]
6. Economic comparison of leflunomide and methotrexate in patients with rheumatoid arthritis: an evaluation based on a 1-year randomised controlled trial. Maetzel A, Strand V, Tugwell P, Wells G, Bombardier C. Pharmacoeconomics; 2002 Jan 23; 20(1):61-70. PubMed ID: 11817993 [Abstract] [Full Text] [Related]
7. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, Fox R, Moreland L, Olsen N, Furst D, Caldwell J, Kaine J, Sharp J, Hurley F, Loew-Friedrich I. Arch Intern Med; 1999 Nov 22; 159(21):2542-50. PubMed ID: 10573044 [Abstract] [Full Text] [Related]
8. Leflunomide: a novel DMARD for the treatment of rheumatoid arthritis. Alldred A, Emery P. Expert Opin Pharmacother; 2001 Jan 22; 2(1):125-37. PubMed ID: 11336574 [Abstract] [Full Text] [Related]
9. [Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany]. Schädlich PK, Zeidler H, Zink A, Gromnica-Ihle E, Schneider M, Straub C, Brecht JG, Huppertz E. Z Rheumatol; 2004 Feb 22; 63(1):59-75. PubMed ID: 14991279 [Abstract] [Full Text] [Related]
10. Leflunomide in monotherapy of rheumatoid arthritis: meta-analysis of randomized trials. Golicki D, Newada M, Lis J, Pol K, Hermanowski T, Tłustochowicz M. Pol Arch Med Wewn; 2012 Feb 22; 122(1-2):22-32. PubMed ID: 22353705 [Abstract] [Full Text] [Related]
11. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gömör B, Van Den Bosch F, Nordström D, Bjorneboe O, Dahl R, Horslev-Petersen K, Rodriguez De La Serna A, Molloy M, Tikly M, Oed C, Rosenburg R, Loew-Friedrich I. Rheumatology (Oxford); 2000 Jun 22; 39(6):655-65. PubMed ID: 10888712 [Abstract] [Full Text] [Related]
12. Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis. Goldenberg MM. Clin Ther; 1999 Nov 22; 21(11):1837-52; discussion 1821. PubMed ID: 10890256 [Abstract] [Full Text] [Related]
13. Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Maetzel A, Strand V, Tugwell P, Wells G, Bombardier C. Arthritis Rheum; 2002 Dec 15; 47(6):655-61. PubMed ID: 12522841 [Abstract] [Full Text] [Related]
14. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Tugwell P, Wells G, Strand V, Maetzel A, Bombardier C, Crawford B, Dorrier C, Thompson A. Arthritis Rheum; 2000 Mar 15; 43(3):506-14. PubMed ID: 10728742 [Abstract] [Full Text] [Related]
16. Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis. Alfaro-Lara R, Espinosa-Ortega HF, Arce-Salinas CA, PRECIS study group, all physicians belong to Division of Internal Medicine. Hospital Central Sur de Pemex. Reumatol Clin (Engl Ed); 2019 Mar 15; 15(3):133-139. PubMed ID: 28867467 [Abstract] [Full Text] [Related]
17. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study. Mladenovic V, Domljan Z, Rozman B, Jajic I, Mihajlovic D, Dordevic J, Popovic M, Dimitrijevic M, Zivkovic M, Campion G. Arthritis Rheum; 1995 Nov 15; 38(11):1595-603. PubMed ID: 7488280 [Abstract] [Full Text] [Related]
20. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany: II. The contribution of leflunomide to efficiency. Schädlich PK, Zeidler H, Zink A, Gromnica-Ihle E, Schneider M, Straub C, Brecht JG, Huppertz E. Pharmacoeconomics; 2005 Nov 15; 23(4):395-420. PubMed ID: 15853438 [Abstract] [Full Text] [Related] Page: [Next] [New Search]